Skip to content
Medical Health Aged Care

Simple immune cell could become ‘off-the-shelf’ rapid tissue, muscle and bone healing therapy

Monash University 2 mins read

Monash University researchers have discovered a cell in the blood which – when introduced to a bone, muscle or skin injury, has the capacity to rapidly promote healing. Importantly these cells can be genetically dissimilar to the recipient, opening up the way for donated blood to be used as a possible universal cell-based therapy for regenerative medicine.

The study, led by Associate Professor Mikaël Martino  from Monash’s Australian Regenerative Medical Research Institute, and published in Nature Communications, showed that these cells, called Regulatory T cells behave like an emergency triage doctor – rapidly becoming a cell type specific for the injury it needs to heal, as well as switching on its genes associated with  immunomodulation and tissue healing.

In addition, these Regulatory T cells regulate other injury healing cells to the site, flooding the injury with beneficial factors. The T cells also actively reduce the accumulation of toxic immune cells which can hamper healing. The studies have been done in animal models using human cells.

According to Associate Professor Martino, this is one of the first times a cell-based approach to injury healing has been used via the administration of immune cells with pro-regenerative abilities. “These Regulatory T Cells have been shown to accumulate within injured tissues - facilitating repair or regeneration in multiple tissues and organs, such as muscle, skin, heart, central nervous system, and lung,” he said.

“Moreover, in animal models these cells have been shown to improve cardiac repair post-heart attack and bone remodelling in osteogenesis imperfecta, or brittle bone disease.”

According to Associate Professor Martino “ these Regulatory T cells can be cultured and kept on the shelf prior to administration which means they could be banked or even become “off the shelf” products which can be injected into injury sites,” he said.

“We expect that augmenting Regulatory T cell numbers locally as early as possible after tissue damage would likely provide the maximum benefit as a therapeutic strategy for tissue healing, and that healing can be further enhanced by the addition of factors they secrete into the injured tissue.”

 


Contact details:

Monash University

Tania Ewing Media and Communications Contractor
E:
tania.ewing1@monash.edu

T: +61 (0) 408 378 422

 

For more Monash media stories, visit our news and events site 


For general media enquiries please contact:
Monash Media
E: media@monash.edu
T: +61 (0) 3 9903 4840

More from this category

  • Disability, Medical Health Aged Care
  • 20/12/2024
  • 17:36
Kuremara

Kuremara to Open a State-of-the-Art Activity Center in Milton, QLD, in January 2025

Kuremara, a trusted and leading NDIS-registered provider in Australia, is excited to announce the opening of its newest facility—a cutting-edge activity center in Milton,…

  • Contains:
  • Legal, Medical Health Aged Care
  • 20/12/2024
  • 17:29
JGA Saddler

BREAKING NEWS: Australian law firm takes on Johnson & Johnson for selling Australians ineffective medicine

Vision available: Lawyer and doctor VNR, editorial photos and radio grabs included can be found in this SharePoint File In-person lawyer interviews available by…

  • Contains:
  • Medical Health Aged Care
  • 20/12/2024
  • 12:01
NDARC/UNSW

ADHD drug shows promise for treating methamphetamine dependence, landmark Australian study shows

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a study published in Addiction. Results from the landmark ‘LiMA’ trial show that thepsychostimulant lisdexamfetamine can drastically reduce the need to use methamphetamine among those who are dependent on the illicit drug. Lead author and addiction medicine specialist Professor Nadine Ezard, who is Director of the National Centre for Clinical Research on Emerging Drugs (NCCRED), said the results were promising. "There is currently no pharmacotherapy approved for treating methamphetamine dependence," Professor Ezard said. “While further…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.